[Inhibitory effects of integrin av beta3 monoclonal antibody on implanted lesions of endometriosis model of SCID mouse].
OBJECTIVE
To explore the potential use of integrin av beta3 (Lm609) monoclonal antibody against ectopic lesion and microvessel angiogenesis of human endometriosis xenografts in SCID mice.


METHODS
The endometrial tissues from endometriosis patients were inoculated subcutaneously into SCID mouse, which were treated with Lm609, an inhibitor of angiogenesis, twice a week, for 3 weeks. The mice were sacrificed and immunohistochemical staining was employed to determine the microvessel density (MVD) and expression of integrin av beta3 in the lesion tissues.


RESULTS
Lm609 inhibited the growth of the ectopic lesion. The lesion weighted 0.82+/-0.09 g in the treated group versus 0.51+/-0.93 g in the control group (P<0.05). The MVDs of the treated and control groups were 31.2+/-4.4 and 14.4+/-1.8 respectively (P<0.05).


CONCLUSIONS
Lm609 can inhibit the growth of ectopic lesion by reducing angiogenesis in SCID mouse.
Zhao
Jun
J
Department of Obstetrics and Gynecology, General Hospital of PLA, Beijing 100853, China.
Zong
Li-li
LL
Li
Ya-li
YL
D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D004715:Endometriosis / Q000473:pathology*; D005260:Female; D039302:Integrin alphaVbeta3 / Q000276:immunology* / Q000502:physiology*; D051379:Mice; D016513:Mice, SCID
D000911:Antibodies, Monoclonal; D039302:Integrin alphaVbeta3